These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 29286865)
1. Randomized Controlled Study to Evaluate the Efficacy of Adalimumab in Patients with Different Forms of Refractory Uveitis. Mackensen F; Heinz C; Jakob E; Grewing V; Lorenz HM; Heiligenhaus A; Max R; Becker MD Ocul Immunol Inflamm; 2018; 26(7):1015-1022. PubMed ID: 29286865 [TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. Suhler EB; Adán A; Brézin AP; Fortin E; Goto H; Jaffe GJ; Kaburaki T; Kramer M; Lim LL; Muccioli C; Nguyen QD; Van Calster J; Cimino L; Kron M; Song AP; Liu J; Pathai S; Camez A; Schlaen A; van Velthoven MEJ; Vitale AT; Zierhut M; Tari S; Dick AD Ophthalmology; 2018 Jul; 125(7):1075-1087. PubMed ID: 29429764 [TBL] [Abstract][Full Text] [Related]
3. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Díaz-Llopis M; Salom D; Garcia-de-Vicuña C; Cordero-Coma M; Ortega G; Ortego N; Suarez-de-Figueroa M; Rio-Pardo MJ; Fernandez-Cid C; Fonollosa A; Blanco R; Garcia-Aparicio AM; Benitez-Del-Castillo JM; Olea JL; Arevalo JF Ophthalmology; 2012 Aug; 119(8):1575-81. PubMed ID: 22525047 [TBL] [Abstract][Full Text] [Related]
4. Comparative study of adalimumab versus conventional therapy in sight-threatening refractory Behçet's uveitis with vasculitis. Yang S; Huang Z; Liu X; Li H; Xie L; Chen X; Wen F; Liang D; Su W Int Immunopharmacol; 2021 Apr; 93():107430. PubMed ID: 33581500 [TBL] [Abstract][Full Text] [Related]
5. Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease--a case cohort interventional study. Sen ES; Sharma S; Hinchcliffe A; Dick AD; Ramanan AV Rheumatology (Oxford); 2012 Dec; 51(12):2199-203. PubMed ID: 22923752 [TBL] [Abstract][Full Text] [Related]
6. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Suhler EB; Lowder CY; Goldstein DA; Giles T; Lauer AK; Kurz PA; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Tessler HH; Smith JR; Rosenbaum JT Br J Ophthalmol; 2013 Apr; 97(4):481-6. PubMed ID: 23376607 [TBL] [Abstract][Full Text] [Related]
7. Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study. Hamam RN; Barikian AW; Antonios RS; Abdulaal MR; Alameddine RM; El Mollayess G; Mansour AM Ocul Immunol Inflamm; 2016 Jun; 24(3):319-26. PubMed ID: 25549063 [TBL] [Abstract][Full Text] [Related]
8. Adalimumab for the treatment of refractory active and inactive non-infectious uveitis. Lee JT; Yates WB; Rogers S; Wakefield D; McCluskey P; Lim LL Br J Ophthalmol; 2018 Dec; 102(12):1672-1678. PubMed ID: 29459430 [TBL] [Abstract][Full Text] [Related]
9. Adalimumab rapidly controls both anterior and posterior inflammation in patients with ocular Behçet syndrome and non-infectious uveitis refractory to conventional therapy: a prospective, 6-month follow-up investigation. Evereklioglu C; Sonmez HK; Sevim DG; Arda H; Sener H; Polat OA; Horozoglu F Int Ophthalmol; 2023 Dec; 43(12):4461-4472. PubMed ID: 37555889 [TBL] [Abstract][Full Text] [Related]
10. Adalimumab for Treatment of Noninfectious Uveitis: Immunogenicity and Clinical Relevance of Measuring Serum Drug Levels and Antidrug Antibodies. Cordero-Coma M; Calleja-Antolín S; Garzo-García I; Nuñez-Garnés AM; Álvarez-Castro C; Franco-Benito M; Ruiz de Morales JG Ophthalmology; 2016 Dec; 123(12):2618-2625. PubMed ID: 27692527 [TBL] [Abstract][Full Text] [Related]
11. Adalimumab therapy for refractory uveitis: a pilot study. Diaz-Llopis M; García-Delpech S; Salom D; Udaondo P; Hernández-Garfella M; Bosch-Morell F; Quijada A; Romero FJ J Ocul Pharmacol Ther; 2008 Jun; 24(3):351-61. PubMed ID: 18476805 [TBL] [Abstract][Full Text] [Related]
12. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Nguyen QD; Merrill PT; Jaffe GJ; Dick AD; Kurup SK; Sheppard J; Schlaen A; Pavesio C; Cimino L; Van Calster J; Camez AA; Kwatra NV; Song AP; Kron M; Tari S; Brézin AP Lancet; 2016 Sep; 388(10050):1183-92. PubMed ID: 27542302 [TBL] [Abstract][Full Text] [Related]
13. Drug Retention Rate and Causes of Discontinuation of Adalimumab in Uveitis: Real-World Data from the Biotherapies in Uveitis (BioÚvea) Study Group. Llorenç V; Cordero-Coma M; Blanco-Esteban A; Heras-Mulero H; Losada-Castillo MJ; Jovani-Casano V; Valls-Pascual E; Jodar-Marquez M; García-Aparicio Á; Fonollosa A; González-Guijarro JJ; Rodriguez-Melian L; Fernández-Prada M; Jerez-Fidalgo M; Hernandez-Garfella M; Esquinas C; Sainz-de-la-Maza M; Adán A; Ophthalmology; 2020 Jun; 127(6):814-825. PubMed ID: 31952883 [TBL] [Abstract][Full Text] [Related]